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Abstract 
Background 
Synaptic protein dyshomeostasis and functional loss is an early invariant feature of 
Alzheimer’s disease (AD), yet the unifying etiological pathway remains largely unknown. 
Knowing that cyclin-dependent kinase 5 (CDK5) plays critical roles in synaptic formation 
and degeneration, its phosphorylation targets were re-examined in search for candidates with 
direct global impacts on synaptic protein dynamics, and the associated regulatory network 
was also analyzed.  
Methods 
Quantitative phospho-proteomics and bioinformatics analyses were performed to identify 
top-ranked candidates. A series of biochemical assays were used to investigate the associated 
regulatory signaling networks. Histological, electrochemical and behavioral assays were 
performed in conditional knockout, shRNA-mediated knockdown and AD-related mice 
models to evaluate its relevance to synaptic homeostasis and functions. 
Results 
Among candidates with known implications in synaptic modulations, BCL2-associated 
athanogene-3 (BAG3) ranked the highest. CDK5-mediated phosphorylation on 
Ser297/Ser291 (Mouse/Human) destabilized BAG3. Loss of BAG3 unleashed the selective 
protein degradative function of the HSP70 machinery. In neurons, this resulted in enhanced 
degradation of a number of glutamatergic synaptic proteins. Conditional neuronal knockout of 
Bag3 in vivo led to impairment of learning and memory functions. In human AD and 
related-mouse models, aberrant CDK5-mediated loss of BAG3 yielded similar effects on 
synaptic homeostasis. Detrimental effects of BAG3 loss on learning and memory functions 
were confirmed in these mice, and such were reversed by ectopic BAG3 re-expression.  
Conclusions 
Our results highlight that neuronal CDK5-BAG3-HSP70 signaling axis plays a critical 
role in modulating synaptic homeostasis. Dysregulation of the signaling pathway directly 
contributes to synaptic dysfunction and AD pathogenesis.  
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Introduction 
Synaptic loss is an early invariant feature of Alzheimer's disease (AD), and that a 
positive relationship exists between the extent of synaptic loss and the severity of dementia 
(1). Synaptic plasticity—the molecular basis of learning and memory—depends heavily on 
the physical composition and structure of synapses (2). Changes in synaptic protein dynamics 
are driven predominantly by the regulation of post-translational modifications, particularly 
protein phosphorylation (2). CDK5 is an atypical cyclin-dependent kinase that is activated not 
by traditional cyclins but cyclin-like activators CDK5R1 (p35 and its calpain-cleaved form: 
p25). Sustained interaction with p25 is believed to activate CDK5 aberrantly, resulting in 
neurodegeneration (3-5). Elevated p25 level is reported in brain regions afflicted by classic 
AD pathologies (5, 6). Known as a tau kinase (7), aberrant CDK5 activity contributes to tau 
hyperphosphorylation and formation of neurofibrillary tangles. CDK5 also phosphorylates 
and activates β-secretase, thereby promoting β-amyloid and plaque formation (8, 9). Together, 
inhibition to aberrantly-activated CDK5 is therefore suggested to be a potential disease 
modulator of AD. However, while some studies support this notion, an increasing amount of 
evidence indicates that adequate CDK5 activity is important for modulating synaptic function 
in post-mitotic neurons. For example, Cdk5r1 knockout mice which confer to dysfunctional 
CDK5 revealed impairments in long-term depression and formation of spatial learning 
memories (10). Alternatively, induction of long-term potentiation (LTP) was also found 
impaired in the neuron-specific Cdk5-conditional knockout mouse model (11, 12).  
 
Based on these findings, CDK5 is known as a classic modulator of synaptic plasticity. At the 
post-synaptic membrane, CDK5 phosphorylates and promotes degradation of 
N-methyl-D-aspartate (NMDA) receptor subunit NR2B, thereby modulates NMDA receptor 
complexes and conductance levels (13). Along the dendrites, the kinase also phosphorylates 
and regulates the stability and abundance of a number of substrates which play crucial roles in 
the formation (e.g. CRMP1, MEF2) and retraction (e.g. WAVE1, ephexin1) of dendritic 
spines (2). Thus, CDK5 is deemed to be an important regulator to facilitate synaptic protein 
turnover. The existing knowledge on known CDK5 substrates suggests that majority of them 
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are fundamental synaptic components. By considering their changes individually however is 
insufficient to explain how CDK5 plays a system role in modulating global synaptic protein 
abundance and homeostasis. In attempt to understand the underlying mechanism, an unbiased 
Stable Isotope Labeling by Amino acids in Cell culture (SILAC) method was deployed to 
re-characterize the phospho-regulatory signaling network resulted from CDK5 activation. 
Among the hits identified, BCL2-associated athanogene-3 (BAG3) was the highest ranked 
candidate with a propensity to regulate global synaptic protein homeostasis. 
 
Autophagy is an effective degradative pathway that digests cellular components and 
maintain cellular proteostasis (14). BAG3 is an emerging regulator of autophagy. It functions 
as a co-chaperone and interacts with heat shock proteins (e.g. HSP70). HSPs involved in 
either facilitating protein folding or regulating protein degradation by ubiquitin-proteasome 
system and autophagy pathways (15, 16), depending on the context of interacting 
co-chaperone (17). Previous studies revealed that BAG3-HSP70 complex favors protein 
refolding and recycling (18-21); however, when BAG3 was replaced, for instance by BAG1 
which contains an ubiquitin-like domain that recruits E3 ligase (e.g. C-terminus of 
HSC70-Interacting Protein, CHIP(22)), the BAG1-HSP70 complex then favors protein 
degradation action (23). HSP70-mediated selective protein degradation is an adaptive 
mechanism in stressed or aging cells for modulating protein homeostasis (24, 25) and in a 
number of diseases including cancer (26, 27) and neurodegenerative disorders (28). 
 
In agreement with previous findings (29-33), our analyses confirmed that BAG3 
localizes in neurites and synaptosomes of mature neurons in the pre-frontal cortex and 
hippocampal regions. Analyses of BAG3 regulatory network revealed that BAG3 is a novel 
target of CDK5. CDK5-mediated phosphorylation at S297 residue promotes BAG3 
degradation. Loss of BAG3, as a result of aberrant CDK5 activation or by direct gene 
knockdown, leads to aberrant HSP70(Hsp1a1)-mediated degradation of synaptic proteins and 
neurotransmitter receptors, and hence impairs synaptic plasticity and LTP in neurons. At 
behavioral level, loss of neuronal BAG3 in the forebrain and hippocampal regions impairs 
memory- and cognitive-related functions. Using Alzheimer’s disease (AD) as a disease model, 
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reductions of BAG3 were observed in post-mortem brain samples of AD patients and 
AD-mice. Further investigation using AD mouse models confirmed that BAG3 is a critical 
modulator of synaptic function in the disease, as deficits in synaptic protein abundance, 
electrophysiological properties of neurons, and cognitive- and memory-related functions were 
rescued upon ectopic re-expression of BAG3. Taken together, our findings revealed 
CDK5-BAG3-HSP70 is a novel signaling axis by which CDK5 commands both the 
maintenance of normal synaptic function as well as the initiation of synaptic functional 
decline in pathological aging brain. 
 
Methods and Materials 
Antibodies and chemical reagents 
Details can be found in Supplementary materials and methods. Unless otherwise 
specified, all reagents were purchased from Sigma.  
 
Animal maintenance, brain tissue harvesting and primary neuronal culture 
All animal experiments were approved by and conducted in accordance with the 
guidelines of the Animal Ethics Committee of Xiamen University and their care was in accord 
with institutional and regional government guidelines. Details of various mice strains and 
sources can be found in Supplementary materials and methods.  
 
Brain tissue harvesting and neuronal culture experiments were performed as previously 
described (34), details can be found in Supplementary materials and methods. 
 
Post-mortem human brain tissues 
Human autopsy tissues from eight individuals diagnosed with AD and eight age-matched 
controls were obtained from the NICHD Brain and Tissue Bank of Developmental Disorders 
at the University of Maryland, Baltimore, MD [NICHD Brain Tissue Bank for Developmental 
Disorders and NICHD (Contract #N01-HD-4-3368 and N01-HD-4-3383)]. Details can be 
found in Supplementary materials and methods. 
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Other experiments 
Details on animal behavioral studies; electrophysiological recordings; western blotting; 
RT-PCR; immunohistology/immunocytochemistry; expression plasmid and small interference 
RNA (siRNA) vector construction; adeno-associated virus production and purification; Golgi 
staining assay; LC-MS/MS and SILAC proteomic analyses; as well as intracranial injection 
assays can be found in Supplementary materials and methods. 
 
Quantitation and statistical analysis 
All data were obtained from at least three separate experiments. Statistical analyses of 
the data were performed using GraphPad Prism 5. All data were presented as the Mean ± 
SEM. P values smaller than 0.05 (P<0.05) represent statistical significance. 
 
Results 
CDK5-mediated phosphorylation on Ser297/Ser291 (Mouse/Human) promotes BAG3 
degradation 
To unbiasedly identify potential targets and signaling network of CDK5 which modulate 
synaptic protein homeostasis, two large-scale, SILAC-based quantitative phospho-proteomics 
experiments were performed in Neuro2a (N2a) cells harboring different levels of CDK5 
activities (Figure 1A). From the unique lists of phospho-peptides enriched in samples with 
activated CDK5 (Table S1-2), we subsequently refined potential CDK5 candidates through 
screening candidates with their phosphorylated serine or threonine residues located prior a 
proline residue (i.e. the canonical p[S/T]P cyclin-dependent kinase (CDK)-targeting motif). 
From this enrichment, 1,591 of them carried the pSP motifs while 143 of them carried pTP 
motifs. A further in-depth analysis on the relative distribution of amino acid residues 
surrounding these phosphorylation sites revealed strong frequencies of arginine (R), histidine 
(H) and lysine (K) residues at position +3 relative to the phosphorylation sites (Figure 1B), a 
pattern revealed that these were likely CDK5-specific targets (35, 36). By applying an 
additional benchmark that allowed only candidates with >1.5-fold phosphorylation 
enrichment to be selected, a subset of 215 phospho-peptide fragments belonging to 160 
proteins was finally enriched (Figure 1A). Functional characterization of these enriched hits 
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using the Ingenuity Pathway Analysis (IPA, Qiagen) revealed 50% of them were clustered. 
Adopting the Gene Ontology (GO) biological function as the clustering parameter, majority 
of the clustered hits played potential roles in neurological disease (Figure 1C). In search for 
the highest ranked candidate with reported roles in regulating synaptic function and protein 
homeostasis, BAG3 was identified (Table S1-2) with phosphorylation at S297 residue 
significantly enriched upon CDK5 activation (Figure 1D). 
To validate BAG3 was truly a CDK5 target, we referenced the canonical CDK5 targeting 
motif [S/T]PX[K/H/R] in which X represents any amino acids and sought for matching amino 
acid sequence motifs on BAG3 (37, 38). Five well-conserved potential CDK5-targeting serine 
or threonine residues on BAG3 were identified (Figure 2A). In vitro kinase assays performed 
in human HEK293T cells released that S297 residue was the only CDK5 target, as 
phosphorylation was completely lost when this residue was mutated into a 
non-phosphorylatable alanine (Figure 2B). To further investigate the phosphorylation of 
BAG3 on S297 by CDK5, we generated an antibody raised against phospho-BAG3 (S297). 
Strong phosphor-signal can be detected in HEK293T cells with ectopic CDK5/P25 expression 
(Figure 2C). We also harvested brain lysates from Embryonic Day 18 old Cdk5 knockout 
mice. Notably, in the absence of CDK5, while phospho-BAG3 level was reduced, yet total 
BAG3 level revealed a reverse trend (Figure 2D). With gene transcription of Bag3 in these 
mice remained unchanged (Figure 2E), this hinted that S297 phosphorylation on BAG3 may 
modulate its protein stability. In reversely prove the observation, ectopic CDK5 expression 
resulted in stronger pBAG3-S297 signal yet a drop in total BAG3 was observed in HEK293T 
cells (Figure 2F). The relevance of CDK5 kinase activity rather than its protein physical 
properties in inducing such phenomenon was confirmed with a CDK5-specific inhibitor, 
roscovitine (Figure 2G). To gain a better understanding on how BAG3 protein became 
downregulated under the influence of CDK5, we modulated protein synthesis and degradation 
properties of the cells. Treatment of protein synthesis inhibitor cycloheximide (CHX) 
revealed that the rate of total BAG3 loss was significantly faster in cells with enhanced CDK5 
activities (Figure 2H). To determine whether the loss of BAG3 induced by CDK5-p25 was 
regulated by the proteasome, we used MG132 to inhibit proteasomal activity after CHX 
treatment. As shown in Figure 2I, the down-regulation of BAG3 by CDK5-p25 shown in 
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Figure 2H was blocked by MG132. Together, these confirmed that CDK5-mediated 
phosphorylation on S297 promotes BAG3 protein degradation. 
 
BAG3 modulates glutamatergic synaptic protein turnover through interacting with 
HSP70  
CDK5 is an important regulator of synaptic plasticity, and that BAG3 is an emerging 
modulator of autophagy, we therefore quested if BAG3 regulates synaptic protein abundance 
and function in the brain. During brain development, level of BAG3 but no other family 
members of BAG (e.g. BAG1 or BAG2) was increased (Figure 3A). The timing of change 
indeed coincided with the postnatal induction time of multiple synaptic proteins (Figure 3A). 
Further subcellular fractionation analysis revealed that BAG3 enriched in postsynaptic 
density fraction (PSD) in DIV21 mature neurons (Figure 3B). This phenomenon was further 
confirmed by immunocytochemistry analysis (Figure 3C). We hypothesized BAG3 at 
synaptic region may interact with local synaptic proteins, therefore we analyzed its potential 
binding partners using LC-MS/MS. In cortical neurons, either overexpressed the GFP-tagged 
BAG3 or GFP protein, co-immunoprecipitation was performed using an anti-GFP antibody. 
Subsequent LC-MS/MS analysis revealed 367 hits from lysates with GFP-tagged BAG3, 
among which 176 hits were commonly identified from lysates with GFP protein. By screening 
out the common hits, 191 unique potential BAG3 binding partners were identified (Figure 3D, 
Table S3). GO biological function analysis revealed that they were likely involved in vesicle 
transport and localization (Figure 3E). Using the alternative Kyoto Encyclopedia of Genes 
and Genomes (KEGG) clustering criteria, 61 pathways were enriched and among the top 10 
pathways were the “Insulin secretion” (Rank 2nd) and Metabolic-related pathways (Rank 3rd to 
5th ) (TCA cycle; Metabolic Pathways and Carbon metabolism) (Figure 3F) which were 
known functions of BAG3 (39, 40). More importantly, the same ranking analysis also 
identified pathways relevant to synaptic function and AD, including “Synaptic vesicle cycle” 
(Rank 1st); Long-term potential (Rank 8th), and Alzheimer’s disease (Rank 6th) (Figure 3F). 
Notably, CDK5R1 (p35/p25) was identified among the binding candidates and it belonged to 
the AD pathway (Figure 3F). A number of presynaptic as well as postsynaptic proteins which 
play important roles in LTP and AD were also identified (Figure 3F, bottom). These included 
9 
 
the presynaptic SYN1; AMPA receptor subunits GLUR1 and GLUR2; NMDA receptor 
subunits NR1 and NR2A, and postsynaptic marker PSD95. Their direct interactions with 
BAG3 were reconfirmed by the in vitro GST-pull down analysis from mouse brain lysates 
using purified GST or GST-Tagged BAG3 harvested from bacteria (Figure 3G). We next 
hypothesized that the loss of BAG3 upon CDK5-mediated phosphorylation indeed plays a 
critical role in synaptic dysfunction. Adeno-associated virus (AAV)-mediated Bag3 
knockdown in neurons significantly reduced a number of synaptic proteins, including SYN1, 
SYP and PSD95 (Figure S1A-C). Subsequently, in vivo analyses were performed by 
stereotactic injection of the AAV into P0 pups (Figure 3H-I). At 90 days after injection, 
chronic effects of Bag3 knockdown was evaluated. Although slight reductions in body 
weights were observed (Figure S1D), significant reductions in synaptic receptor proteins, 
including GLUR1, GLUR2, NR1 and NR2A were observed in the prefrontal cortex (Figure 
3J). Histological Golgi staining was performed, which revealed impaired neuronal 
arborization and reduced number of dendritic spines in both hippocampal (Figure 3K) and 
prefrontal cortex (Figure S2A-D) regions in these mice. To further confirm the above 
observation, neuronal-specific Bag3 conditional knockout mice (Nestin-Cre/Bag3f/f) were 
generated and these mice grow normally (Figure S3A-D). We observed significantly 
decreasing of BAG3 and synaptic components like GLUR1 and NR1 in both hippocampus 
and cortex of these animals (Figure S3E-F).  
 
To understand the mechanism behind BAG3 modulation of synaptic protein and receptor 
abundances, we explored its co-chaperone role in regulating protein homeostasis (41, 42). On 
the list of BAG3 interacting partners (Table S3), family members of HSP70 including HS12A 
(Hspa12a), HS74L (Hspa4l), HSP74 (Hspa4) and HSP70/HSP72 (Hspa1a) were identified. 
HSP70/HSP72 (Hspa1a) promotes the degradation of target proteins through direct 
protein-protein interaction (43, 44) and that the presence of BAG3 as a competitor suppresses 
this mechanism (45, 46). To confirm if HSP70 targets synaptic proteins and share similar 
interactome as that of BAG3 in neurons, we overexpressed GFP-tagged HSP70/HSP72 
(Hspa1a) or GFP control in neurons, followed by co-immunoprecipitation assay with 
anti-GFP antibody and LC-MS/MS analysis. A total of 426 hits were identified from the 
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GFP-HSP70 pulldown, among which 137 overlapped with those identified from the GFP 
controls, 289 hits were uniquely found which included BAG3 (Figure 4A, Table S4). 
Subsequent GO Biological pathway clustering analyses of these enriched hits revealed their 
potential roles in vesicle-mediated transport and its regulation (Figure 4B). Alternative 
analysis with KEGG clustering criteria again revealed their roles in synaptic structures 
(“synaptic vesicle cycle”; “glutamatergic synapse” and “dopaminergic synapse”), functions 
(“long-term potentiation”) and a number of neuro-pathological conditions (“amphetamine 
addiction”; “Alzheimer’s disease” and “Huntington’s disease”) (Figure 4C). Together, these 
confirmed that HSP70 action is important for synaptic modulation in neurons. Using the hits 
identified, comparative analysis between the 289 and 191 interacting proteins of HSP70 and 
BAG3, respectively, was performed; and that 68 common interacting partners were identified 
(Figure 4D, Table S5). Pathway analyses again revealed they were involved in synaptic 
vesicle structure and transport function and a number of neuropathological conditions. (Figure 
4E-F). To evaluate if CDK5-mediated loss of BAG3 consequently unleashes HSP70 for 
synaptic protein interaction and degradation, we utilized the p35 and p25 ectopic expression 
system to modulate endogenous CDK5 activities (Figure 4G). With advancing activities of 
CDK5 from p35- to p25-overexpressing cells, phosphorylated BAG(S297) level increased 
while total BAG3 decreased (Figure 4G). Interaction between BAG3 and HSP70 was 
consequently diminished, which the latter revealed enhanced interactions with synaptic 
components (e.g. GLUR1 and SYN1) even their total levels reduced (Figure 4G). The role of 
HSP70/HSP72 in aberrant CDK5-activity mediated synaptic protein degradation was further 
validated by Hspa1a knockdown, where aberrant loss of GLUR1 and SYN1 in cells 
overexpressed p25 was prevented (Figure 4H). 
 
BAG3 is crucial for glutamatergic transmission, long-term potential and memory 
formation 
Based on the findings at both molecular and cellular levels, we then evaluated the 
electrophysiological properties in neurons. Mice with Bag3 knockdown in the hippocampus 
region revealed impairments in input/output function for basal synaptic transmission (Figure 
5A). Further investigation of neuronal response to paired-pulse facilitation (PPF) showed 
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reduction of synaptic facilitation at these synapses (Figure 5B). Glutamatergic 
neurotransmission also revealed deficits in both frequency and amplitude of AMPA- or 
NMDA-receptor-mediated mEPSCs and eEPSCs (Figure 5C-D, Figure S4A-B). Consequently, 
long-term potentiation (LTP) induced by high-frequency stimulation was also impaired 
(Figure 5E). A similar response was also found in the 2-month old Nestin-Cre/Bag3f/f 
conditional knockout mice (Figure S5A). Despite these changes, no differences were 
observed in gamma-aminobutyric acid (GABA) receptor-mediated mIPSCs and eIPSCs 
(Figure S4C-G). Together, electrophysiology recording emphasized BAG3 is crucial for 
maintaining synaptic functions in mature neurons, in particular, glutamatergic transmission 
mediated by AMPA and NMDA receptors.  
 
To understand how these impairments manifest to deficits in animal behaviors, a battery 
of behavioral analyses were performed. Using the Morris water maze (MWM) paradigm, 
mice with Bag3 knockdown in the hippocampus revealed longer escape latency (Figure 5F) 
and exploration time at the target quadrant (Figure 5G), and fewer entries and longer initial 
latency time to the target quadrant (Figure 5H). Similar impairments were also observed in 
the 2-month old Nestin-Cre/Bag3f/f mice (Figure S5B-E). By the novel object recognition 
paradigm, while preference to a familiar object was found to be indifferent, frequencies of 
novel object exploration was significantly reduced in Bag3 knockdown mice (Figure 5I). 
Further analyses with the T-maze and Y-maze alternation paradigms revealed that Bag3 
knockdown impaired working memories (Figure S5F-G). In contrast to these cognitive and 
memory-related functions, Bag3 knockdown did not induce any anxiety (evaluated by 
elevated-plus maze and open-field test); depression (evaluated by forced-swimming test) and 
locomotor incapability (evaluated by Rotarod test) (Figure S5H-K).  
 
BAG3 level is reduced in Alzheimer’s disease (AD) brain and its ectopic expression 
rescued synaptic and functional deficits in AD-related mouse models 
Loss of memory and cognitive abnormalities are among the first symptoms reported in 
patients suffering from AD (47). At cellular level, aberrant CDK5 activity caused by p25 was 
previously reported in AD, this phenomenon could be induced by incubating primary neurons 
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with a mix of fibrillated and oligomeric amyloid-β (Aβ1-42) over a 6-hour time course (Figure 
6A). Phosphorylated BAG3 at S297 and total BAG3 levels again revealed an opposite trend 
of progression along the treatment time, in which the changes were prevented when sufficient 
amount of Cdk5 was knockdown (Figure 6B). The effect of accumulation of humanized 
amyloid-β on BAG3 was also revealed in brain lysates of PS1/APP (Figure 6C-D) and 
5XFAD AD-mouse models (Figure S6A). Extending this to human, total BAG3 was 
significantly reduced in post-mortem human AD brain samples, particularly in neurons 
(Figure 6E-F). To test whether BAG3 expression could rescue synaptic deficits and impaired 
learning and memory defects in AD mice, we specifically generated an AAV construct in 
which BAG3 is expressed using a CMV promoter (AAV-BAG3) (Figure 7A). We next 
injected AAV-BAG3 or an AAV-GFP control into hippocampus of 5XFAD mice to 
specifically restore BAG3 expression in vivo (Figure 7A-B). Western blotting analysis 
revealed that ectopic expression of BAG3 restored levels of GLUR1, SYN1, SNAP25 and 
SYP, which was likely a result of reduced interaction with HSP70 (Figure S6B-C). Next, we 
found that BAG3 ectopic expression rescued escape latency deficits during training and 
improved time spent in the target quadrant in Morris water maze tests (Figure 7C-D). 
Additionally, LTP deficits observed in 5XFAD mice were also restored by AAV-BAG3 
expression (Figure7E). 
 
Discussion 
In this report, we showed that BAG3 is a CDK5 target with crucial roles in modulating 
synaptic protein turnover. CDK5-mediated phosphorylation on S297 triggers protein 
degradation of BAG3. Reduced BAG3 unleashes HSP70, results in aberrant interaction and 
degradation of multiple synaptic proteins in neurons. At cellular level, BAG3 loss selectively 
reduces glutamatergic synaptic proteins, neurite complexity and synaptic pruning, which 
subsequently impairs glutamatergic firing, LTP and hippocampal-dependent memory and 
cognitive functions. Dysregulation of BAG3 also contribute to synaptic dysfunction during 
AD pathogenesis. In AD-mouse model, BAG3 re-expression reduced synaptic deficits, 
electrophysiological and behavioral levels. Our study identifies a new CDK5 phosphorylation 
target and a regulatory mechanism which explain how the kinase systematically modulates 
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synaptic protein homeostasis and neurotransmission (Figure S7). 
 
As a regulator of autophagy, BAG3 integrates into the cellular chaperone network in 
which competition and cooperation among different co-chaperones governs the formation of 
functionally distinct chaperone complexes (48-50). With reference to the reciprocal 
relationship between BAG1 and BAG3 expression levels during the process of cellular aging, 
as well as its uniqueness in utilizing HSP70 chaperones in the autophagy pathway found in 
other cellular system (25), we report here that this mechanism is in play in during neuronal 
maturation. In mature neurons, reduced BAG3 results in impairment of synaptic abundance 
function, inducing deficits in cognitive and memory functions. A recent report revealed that 
selective BAG3 reduction in excitatory neurons exacerbated tau accumulation, contributing to 
cellular vulnerability to tau pathology (51). Indeed, our data echo with their findings from 
different perspectives. We identified BAG3 is a novel target of CDK5, a classic tau kinase. 
Aberrant CDK5 activity downregulates BAG3, which the activated kinase also introduces tau 
hyperphosphorylation. On the other hand, our data revealed that BAG3-HSP70 machinery 
selectively interacts and targets glutamatergic synaptic proteins. Loss of BAG3 leads to 
aberrant loss of these synapses and functions, resulting in cognitive and memory impairment 
in mice. Aberrant ubiquitination and degradation of glutamatergic synaptic proteins are 
reported in contributing to the pathogenesis of AD (52-54). We speculated that if the 
reciprocal relationship between BAG1 and BAG3 on regulating HSP70 function exists in 
mature neurons, loss of BAG3 would favor BAG1-HSP70 interaction, hence promoting E3 
ligase-dependent proteasome degradation of glutamatergic synaptic proteins (55). It would be 
interesting to know as well if the action of HSP70 machinery is involved BAG3 effect on tau 
accumulation (51), and these details warrant future investigation.  
 
The maintenance of healthy synapses keeps a delicate balance between synaptic protein 
synthesis and degradation (56). While many reports attribute the loss of synaptic function to 
reduced biosynthesis of these proteins (57-59), here we provide evidence to support an 
alternative mechanism which reduction of synaptic proteins could be a result of aberrant 
HSP70-mediated degradation in conditions where BAG3 was lost. In the nervous system, 
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HSP70 family members are induced in response to injuries and stress conditions like stroke, 
epilepsy or trauma (60). Depending on the cellular context and conditions, enhanced 
expression of HSP70 can be either neuroprotective or neurotoxic (60-62). For example, 
pharmacological induction of HSP70 in a mouse model of amyotrophic lateral sclerosis 
resulted in caspase-mediated apoptosis of motor neurons (63); while mixed effects of HSP70 
function were observed in a kainic acid (KA)-induced epilepsy model (62, 64). We propose 
that such inconsistencies indicated that complex regulatory mechanisms exist in modulating 
HSP70 actions. Here we show that CDK5-BAG3-HSP70 signaling axis is one of these 
examples. CDK5 is an important regulator of different synaptic proteins and neurotransmitter 
receptors (65-69).  
Here we propose a novel mechanism by which CDK5 modulates synaptic function in a 
systematic manner—by regulating the BAG3-HSP70 autophagy network. Although our data 
ascribed a neurotoxic outcome to the activation of CDK5, it is important to recall that timing 
and duration is an important facet of this phenomenon. This is so because transient CDK5 
activation is not pathological, but rather an essential part of synaptic plasticity and the 
formation of hippocampus-dependent memory (70). Our findings are the first to link the 
chronic activation of CDK5 with the previously unrecognized BAG3-HSP70 relationship, 
further supporting our model of synaptic protein modulation. By regulating the strength and 
duration of BAG3-HSP70 interaction, CDK5 activity coordinates the turnover of 
glutamatergic synaptic proteins and maintains their concentrations within the appropriate 
range. The balance between synaptic protein synthesis and degradation is needed for late LTP 
to occur, as co-application of protein degradation blockers and translational inhibitors is able 
to restore late LTP, which is otherwise blocked when these inhibitors are applied separately 
(71). Our finding again explains the dynamic effect CDK5 has on synaptic strength and 
circuit dynamics in the nervous system. With strategies like pharmacological intervention 
against CDK5 activity being proposed for AD and other neuropathological conditions (72). It 
is important to remember that either a chronic blockade of activity or a sustained gain of 
function would both disrupt the normal BAG3-HSP70 dynamics. Going forward, it will be 
important to study whether there are compartment-specific characteristics of the synthesis and 
degradation machinery and how these events are exactly coordinated in the future. 
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Figure 1. Stable isotope labelling by amino acids in cell culture (SILAC) analysis for 
CDK5 phospho-proteome. (A) Schematic diagram of the experimental flow of SILAC 
experiment. Bottom plots indicate the ratio distribution of phospho-peptides identified in each 
set of screening. (B) Binomial distribution of amino acids at positions flanking or lagging the 
CDK5-targeting serine (S) or threonine (T) residues in enriched (log2H/L>1.5 or 2) 
phosphor-peptides identified form the SILAC experiments. (C) Ingenuity pathway analysis 
was performed using the GO Biological Function paradigm. The top 10 enriched pathways 
are shown. (D) Mass spectrometry profiles of the p35 or the CDK5/p35 SILAC screens reveal 
BAG3 phosphorylation at Serine 297 residue (S297) was commonly enriched. Unless 
otherwise specified, all experiments were performed with at least 3 biological repeats; each 
individual assay was performed at least three times. 
 
Figure 2. CDK5-mediated phosphorylation on S297 promotes BAG3 degradation. (A) 
BAG3 protein sequences of multiple species were aligned using the Clustal Omega platform. 
Conserved S/TP sites were highlighted in red. (B) Representative blots of in vitro CDK5 
kinase assays. Phosphorylation on the recombinant GST-tagged BAG3 mutant proteins was 
tested in vitro in the presence of active CDK5/p35 complex. Reaction products were 
immunoblotted with CDK5 target specific p[S/T]P antibody. Coomassie blue staining 
indicates equal loading. (C) Representative blots showing signals of S297 phosphorylation 
[pBAG(S297)] on V5-tagged BAG3 are present only when GFP-tagged CDK5 and p25 were 
co-expressed in HEK293T cells. (D) Representative blots showing changes in pBAG3(S297) 
and BAG3 in response to CDK5 level in Embryonic 18 Day Cdk5 wildtype, heterozygous and 
homozygous knockout mice. Both frontal cortex and hippocampal tissues were analyzed. 
Quantifications are shown on the right (N=6). (E) Quantitative PCR of Bag3 gene expression 
in both cortex and hippocampal tissues harvested from wildtype, heterozygous and 
homozygous Cdk5 knockout mice (N=6). (F) Representative blots showing changes in 
pBAG3(S297) and BAG3 levels in accordance with different levels of CDK5 activities in 
HEK293T cells. Quantifications are shown below (N=6). (G) Representative blots showing 
changes in pRB, pBAG3(S297) and BAG3 levels in response to pharmacological inhibition of 
CDK5 by roscovitine for different time courses. Quantifications of band intensity and cellular 
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CDK5 activity in all treatment time courses are shown. (H) Representative blots showing 
changes in total BAG3 level in cells of different CDK5 activities subjected to cycloheximide 
treatment for different time courses. Quantification is shown on the right (N=6). (I) HEK293T 
cells transfected with GFP-CDK5/p25 were first treated with CHX for 8 hours, and followed 
50 µM MG132 treatment for 2 hours. Representative blots showing changes in total BAG3. 
Quantification is shown on the right (N=6). Unless otherwise specified, all experiments 
performed with at least 3 biological repeats, each individual assay was performed at least 
three times. *P<0.05, **P<0.01, ***P<0.001, ns=non-significant. Data represent the mean ± 
SEM. 
 
Figure 3. BAG3 sustains synaptic protein abundance. (A) Representative blots showing 
changes of BAG1/2/3, SYN1, NR2A and GLUR1 during neuronal maturation. Quantification 
is shown (N=6). (B) Representative blots showing enrichments of BAG3 in synaptic fractions 
enriched from DIV21 primary neurons. Quantification is shown (N=6). (C) Representative 
immunocytochemistry images showing the distribution of BAG2/3 at synaptic regions of 
DIV21 primary neurons. Quantification is shown (N=6). (D) Venn diagram shows among the 
367 hits identified from GFP-BAG3 pulldown; 176 hits overlapped with those identified from 
the GFP pull-down using LC-MS/MS analysis (N=6). (E-F) 191 unique GFP-BAG3 
interacting partners were clustered using (E) Gene Ontology and (F) KEGG parameters, top 
10 enriched pathways are shown. At the bottom of (F) are lists of proteins enriched in 
corresponding KEGG pathways. (G) In vitro pull-down assay of proteins from mouse 
forebrain lysates using purified GST or GST-Tagged BAG3 harvested from bacteria, was 
performed. Representative blots showing BAG3 interaction with various synaptic proteins 
(N=6). (H) Schematic diagram of the structure of the shRNA-BAG3-GFP shuttle and 
associated workflow in mice. (I) Representative image of AAV-GFP signals in mice reveals 
viral transduction occurred predominantly in the pre-frontal cortex and hippocampal regions 
(N=6). (J) Representative blots showing changes in BAG3, pBAG3(S297), GLUR1, GLUR2, 
NR1, NR2A and CDK5 in cortical tissues harvested from mice received either 
AAV-Scrambled shRNA or AAV-Bag3-shRNA for 90 days. Quantification is shown (N=6). 
(K) Representative images of Golgi staining of neurite structures and dendritic spines in 
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hippocampal tissues harvested from mice received either AAV-Scrambled shRNA or 
AAV-BAG3-shRNA for 30 days. Quantification of spine number is shown (N=6) Unless 
otherwise specified, all experiments performed with at least 3 biological repeats; each 
individual assay was performed at least three times. *P<0.05, **P<0.01, ***P<0.001, 
ns=non-significant. Data represent the mean ± SEM. 
 
Figure 4. BAG3 prevents HSP70-synaptic protein interaction hence sustains their 
abundance. (A). Venn diagram shows among the 426 hits identified from GFP-HSP70 
pulldown; 137 hits overlapped with those identified from the GFP pull-down using 
LC-MS/MS analysis (N=6). (B-C) 289 unique GFP-HSP70 interacting partners were 
clustered using (B) Gene Ontology and (C) KEGG parameters, top 10 enriched pathways are 
shown. At the bottom of (C) are lists of proteins enriched in corresponding KEGG pathways. 
(D) Venn diagram shows 68 common binding partners identified among different set of 
unique binding partners of BAG3 (Figure 3D) and HSP70. (E-F) 68 common interacting 
partners were clustered using (E) Gene Ontology and (F) KEGG parameters, top 10 enriched 
pathways are shown. At the bottom of (F) are lists of proteins enriched in corresponding 
KEGG pathways. (G) Representative blots showing changes in total levels as well as 
protein-protein interactions of BAG3, HSP70 and selected synaptic protein levels in neurons 
ectopically expressed GFP-tagged p35 or p25. Quantification of bands (N=5) as well as 
corresponding CDK5 activities in different groups are shown (N=9). (H) Representative blots 
showing changes in total levels as well as protein-protein interactions of BAG3, HSP70 and 
selected synaptic protein levels in neurons ectopically expressed GFP-tagged p25, together 
with scrambled siRNA or Hspa1a siRNA. Quantification of bands (N=8) as well as 
corresponding CDK5 activities in different groups are shown (N=9). Unless otherwise 
specified, all experiments performed with at least 3 biological repeats; each individual assay 
was performed at least three times. *P<0.05, **P<0.01, ***P<0.001, ns=non-significant. 
Data represent the mean ± SEM. 
 
Figure 5. BAG3 is indispensable for glutamatergic firing, long-term potentiation and 
memory formation. (A-E) Electrophysiology recordings in brain slices harvested from mice 
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stereotaxically injected AAV carrying GFP-tagged scrambled shRNA or GFP-tagged Bag3 
shRNA shuttles. Recordings were performed on Day30 post-injection. (A) fEPSP input-output 
relationship was recorded in hippocampal CA1 region upon stimulation at the superior 
colliculus region (N=6). (B) Whole-cell eEPSC pair-pause ratio recording patter recorded in 
hippocampal CA1 pyramidal neurons (N=6). (C-D) Representative tracing patterns of (C) 
AMPA receptor- and (D) NMDA receptor-mediated mEPSCs. All recordings were performed 
at a holding potential of -65mV. Quantitative analyses of corresponding receptor-mediated 
mEPSC frequencies and amplitudes are shown (N=6). (E) LTP recording in superior 
colliculus after induction of a train of 100-Hz stimuli. Insets: representative traces of fEPSP 
responses prior and at 50-min post-high frequency stimulations. Quantitative analyses of 
fEPSP slopes are shown and the level of fEPSP potentiation was determined by averaging the 
values between 0 to 3 min and 50 to 60 min post-high frequency stimulations (N=6). (F-H) 
Morris water maze test was performed in mice stereotaxically injected AAV carrying 
GFP-tagged scrambled shRNA or GFP-tagged Bag3 shRNA shuttles. Recordings were 
performed on Day 90 post-injection. (F) Escape latency trajectory pattern of the initial 6-day 
training phase is shown (N=6). (G) Time spent in the target zone and other quadrants (NE, SE 
and SW), as well as (H) the frequency of target zone crossing; and initial time required for 
reaching the target platform during the probe trial performed on Day7 are shown (N=6). (I) 
Novel object recognition analysis was performed on Day 90 post-injection. Frequencies of 
mice accessing familiar (object A) versus novel (object B) objects were recorded. Exploration 
time was analyzed and shown (N=6). Unless otherwise specified, all experiments performed 
with at least 3 biological repeats; each individual assay was performed at least three times. 
*P<0.05, **P<0.01, ***P<0.001, ns=non-significant. Data represent the mean ± SEM. 
 
Figure 6. BAG3 is reduced in Alzheimer’s disease (AD). (A) Representative blots showing 
changes in phosphorylated pBAG3(S297), total BAG3, CDK5R1 (p35/p25), CDK5 and 
HSP70 in neurons exposed a mixture of fibrillated and oligomeric amyloid-β (Aβ1-42) peptide 
for various time courses. Quantification is shown (N=6). (B) Representative blots showing 
changes in phosphorylated pBAG3(S297), total BAG3, CDK5R1 (p35/p25), CDK5 and 
HSP70 performed in neurons with or without Cdk5 knockdown, and exposed a mixture of 
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fibrillated and oligomeric amyloid-β (Aβ1-42) peptide for 6 hours. Quantification is showed 
(N=6). (C) Brain cortical samples harvested from 12-month old PS1/APP mice and 
non-transgenic littermates were analyzed. Representative blots showing differences in 
phosphorylated pBAG3(S297), total BAG3, CDK5R1 (p35/p25), CDK5 and HSP70 are 
shown (N=12). Corresponding CDK5 activities (N=6); as well as correlations between (i) 
pBAG3/GAPDH or (ii) BAG3/GAPDH to p25/GAPDH ratio are shown (N=12). (D) 
Representative immunohistochemistry images of BAG3 and MAP2 signals in prefrontal 
cortex regions of PS1/APP mice and littermates are shown (n=10). (E) Post-mortem frozen 
brain samples from AD patients and non-demented age-matched control were analyzed. 
Representative blots showing differences in phosphorylated pBAG3(S297), total BAG3, 
CDK5R1 (p35/p25), CDK5 and HSP70 are shown (N=9); Corresponding CDK5 activities 
(N=6); as well as correlations between (i) pBAG3/GAPDH or (ii) BAG3/GAPDH to 
p25/GAPDH ratio are shown (N=9). (F) Representative immunohistochemistry images of 
BAG3 and MAP2 signals in frontal cortex regions of post-mortem frozen human AD and 
non-demented age-matched samples (N=9). Unless otherwise specified, all experiments 
performed with at least 3 biological repeats; each individual assay was performed at least 
three times. *P<0.05, **P<0.01, ***P<0.001, ns=non-significant. Data represent the mean ± 
SEM. 
 
Figure 7. Ectopic expression BAG3 rescued synaptic and functional deficits in 5XFAD 
AD-mouse model. (A) Schematic diagram shows the construct design for GFP-tagged BAG3, 
and the experimental workflow. AAV carrying this construct was stereotaxically delivered to 
hippocampal CA1 region of 4-month old 5XFAD mice. (B) Representative 
immunohistochemistry images showing GFP-fluorescence and total BAG3 signals in CA1 
hippocampal region of 5XFAD mice at 5-weeks post-AAV injections. (C-D) Morris water 
maze (MWM) test for spatial learning memory was also performed in these mice. (C) The 
initial latency to target during the 6-day training course was recorded (N=6-7). (D) During the 
probe trial test on Day 7, the time spent by these mice in the target zone and other quadrants 
(NE, SE and SW) were recorded (N=6-7). (E) Ectopic expression of BAG3 rescued LTP 
deficits in hippocampal CA1 region of 5-months old 5XFAD mice. LTP was recorded by 
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inducing two trains of 100-Hz stimuli at Schaffer Collaterals. A significant difference in 
fEPSP potentiation was determined by comparing fEPSP slopes during last 10 min of 
recording after high frequency stimulations (N=6-7). Unless otherwise specified, all 
experiments performed with at least 3 biological repeats; each individual assay was 
performed at least three times. *P<0.05, **P<0.01, ***P<0.001, ns=non-significant. Data 
represent the mean ± SEM. 
 
 







Resource Type Specific Reagent or Resource Source or Reference Identifiers Additional Information
Add additional rows as 
needed for each resource 
type
Include species and sex when applicable.
Include name of manufacturer, company,  repository, 
individual, or research lab. Include PMID or DOI for 
references; use “this paper” if new.
Include catalog numbers, stock numbers, database IDs or accession 
numbers, and/or RRIDs. RRIDs are highly encouraged; search for 
RRIDs at https://scicrunch.org/resources. Include any additional information or notes if necessary.
Antibody Rabbit anti-CDK5 Cell Signaling Technology 2506
Antibody Rabbit anti-phospho-CDK Substrate Motif Cell Signaling Technology 9477S
Antibody
Rabbit anti-pBAG3(S297) ProSci Incorporated Custom made
Rabbits were immunized with BAG3 phosphopeptide 
(PLHSP(pS)PIRVH) to induce immune response. Subsequent serum 
fractionation with both negative- and positive-affinity purification 
methods was performed to optimize the specificity for the targeted 
phosphoepitope
Antibody Rabbit anti-PSD95 Cell Signaling Technology 3450S
Antibody Rabbit anti-cleaved caspase-3 Cell Signaling Technology 9661S
Antibody Rabbit anti-β-actin Cell Signaling Technology 4970S
Antibody Rabbit anti-phospho-Rb (Ser807/811) Cell Signaling Technology 9308S
Antibody Rabbit anti-GAPDH Cell Signaling Technology 5174S
Antibody Mouse anti-CDK5 Santa Cruz Biotechnology sc-6247
Antibody Rabbit anti-GFP Santa Cruz Biotechnology sc-8334
Antibody Rabbit anti-p35 (C-terminal) Santa Cruz Biotechnology sc-820
Antibody Rabbit anti-p35 (N-terminal) Santa Cruz Biotechnology sc-821
Antibody Goat anti-V5 probe Santa Cruz Biotechnology sc-83849
Antibody Mouse anti-GAPDH Santa Cruz Biotechnology sc-47724
Antibody Mouse anti-a-tubulin Santa Cruz Biotechnology sc-8035
Antibody Mouse anti-a-tubulin Sigma Aldrich T5168
Antibody Rabbit anti-Synaptophysin Sigma Aldrich SAB4502906
Antibody Mouse anti-FLAG Sigma Aldrich A2220
Antibody Rabbit anti-BAG3 Abcam ab86298
Antibody Goat anti-PSD95 Abcam ab12093
Antibody Rabbit anti-Syntaxin I Immunoway YT5440
Antibody Mouse anti-CDK5 Millipore 05-364
Antibody Rabbit anti-synapsin I Millipore AB1543
Antibody Rabbit anti-NR2A Millipore 07-632
Antibody Mouse anti-GST tag ProteinTech HRP-66001
Antibody Rabbit anti-GLUR1 Abcam ab31232
Antibody Rabbit anti-GLUR2 Abcam ab20673
Antibody Rabbit anti-NR2B Abcam ab65783
Antibody Rabbit anti-BAG1 Thermo Fisher PA5-29585
Antibody Rabbit anti-BAG2 Thermo Fisher PA5-30922
Antibody Rabbit anti-BAG3 Thermo Fisher PA5-54239
Antibody Mouse anti-HSP70 Thermo Fisher MA3-006
Antibody Rabbit anti-beta-amyloid GeneTex GTX82974
Antibody Rabbit anti-APP GeneTex GTX101336
Antibody Goat anti-mouse ALEXA 488 Thermo Fisher A28175
Antibody Goat anti-mouse ALEXA 594 Thermo Fisher A-11005
Antibody Goat anti-rabbit ALEXA 488 Thermo Fisher A27034
Antibody Goat anti-rabbit ALEXA 594 Thermo Fisher A-11012
Bacterial or Viral Strain AAV-CMV-GFP-WPRE-pA BrainVTA biotech Custom-made
Bacterial or Viral Strain AAV-CMV-BAG3-GFP-WPRE-pA BrainVTA biotech Custom-Made
Bacterial or Viral Strain AAV-CAG-EGFP-U6-scramble-shRNA OBiO biotech Shanghai Custom-Made
Bacterial or Viral Strain AAV-CAG-EGFP-U6-shBAG3-1-3 OBiO biotech Shanghai Custom-Made
Organism/Strain C57BL/6 Xiamen University Laboratory Animal Center N/A
Organism/Strain 5XFAD [B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax]Model Animal Rese rch Center of Nanjing University N/A
Organism/Strain APP/PS1 [B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax]Model Animal Research Center of Nanjing University N/A
Organism/Strain Nestin-Cre [B6.Cg-Tg(Nes-cre)1Kln/J] Model Animal Research Center of Nanjing University N/A
Organism/Strain BAG3-conditional knockout (cKO) mice (BAG3Beijing Biocytogen Co., Ltd Custom-made
Organism/Strain
C57BL/6 
Animal and Plant Care Facility of the Hong Kong 
University of Science and Technology
Organism/Strain Camk2a-tTa [B6;CBA-Tg(Camk2a-tTa)1Mmay/J]Jackson Laboratory #003010
Organism/Strain APP/PS1 [B6C3- Tg(APPswe,PSEN1dE9)85Dbo/Mmjax]Jackson Laboratory #34829-JAX
Organism/Strain p25 [C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J] ackson Laboratory #005756
Organism/Strain CDK5-knockout [B6;129-Cdk5tm1Kul/J] Jackson Laboratory #006388
Biological Sample
Human autopsy tissues 
NICHD brain and Tissue Bank of Developmental Disorders 
at the University of Maryland, Baltimore, MD Contract #N01-HD-4-3368 and N01-HD-4-3383)
Cell Line HT-22 Mouse Hippocampal Neuronal Cell LineMillipore SCC129
Cell Line Neuro 2A ATCC ATCC® CCL-131™
Cell Line HEK293T ATCC ATCC® CRL-3216™
Cell Line HEK293FT Thermo Fisher R70007
Chemical Compound or DrugRoscovitine Tocris Cat. No. 1332
Chemical Compound or DrugLipofectamine 2000 Thermo Fisher 11668027
Chemical Compound or DrugLipofectamine LTX with Plus reagent Thermo Fisher 15338100
Commercial Assay Or Kit RNeasy mini kit Qiagen 74104
Commercial Assay Or Kit High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814
Commercial Assay Or Kit SYBR Green PCR Master Mix Applied Biosystems 4309155
Commercial Assay Or Kit FD Rapid Golgi Stain kit FD NeuroTechnologies PK401
Commercial Assay Or Kit Site-Directed Mutagenesis Kits (Quickchange II)Agilent Strategene 200521
Commercial Assay Or Kit Lentivirus-Associated p24 ELISA Kit Cell Biolabs VPK-107
Commercial Assay Or Kit Micro BCA protein assay kit Thermo Fisher 23235
Commercial Assay Or Kit Pierce™ GST Protein Interaction Pull-Down KitThermo Fisher 21516
Commercial Assay Or Kit Titansphere Phos-TiO kit Fisher Scientific NC9738209
Peptide, Recombinant ProteinHuman amyloid-beta peptide (1-42) Tocris #1428
Sequence-Based Reagent Mouse Hspa1a siRNA Thermo Fisher AM16708
Sequence-Based Reagent Mouse Cdk5 siRNA Thermo Fisher AM16708
Sequence-Based Reagent Mouse Bag3 siRNA Thermo Fisher AM16708
Software; Algorithm Protein sequences alignment Clustal Omega Platform https://www.ebi.ac.uk/Tools/msa/clustalo/
Software; Algorithm Protein sequences idnetification NCBI Gene database https://www.ncbi.nlm.nih.gov/gene 
Software; Algorithm Freeze Frame software Actimetrics N/A
Software; Algorithm Mini Analysis software Synaptosoft, Inc N/A
Software; Algorithm Graphpad Prism 5 Graphpad N/A
Transfected Construct psPAX2 Addgene #12260
Transfected Construct pMD2.G Addgene #12259
Transfected Construct GFP-BAG3-WT Made in house N/A
Transfected Construct GFP-BAG3-S297A Made in house N/A
Transfected Construct GFP-BAG3-S297D Made in house N/A
Transfected Construct GFP-BAG3-T285A Made in house N/A
Transfected Construct GST-BAG3-WT Made in house N/A
Transfected Construct GST-BAG3-S297A Made in house N/A
Transfected Construct GST-BAG-297D Made in house N/A
Other Magnetic Dynabeads Protein G 
Immunoprecipitation Kit Thermo Fisher 10007D
KEY RESOURCES TABLE
Zhou et al.  Supplement 
1 
 
Cyclin-Dependent Kinase 5-Dependent BAG3 Degradation 
Modulates Synaptic Protein Turnover 
 
Supplement 1  
 
 
Contents: 
Detailed Supplemental Methods and Materials 
Supplementary Figures 
Supplementary Table Legends 
Supplemental References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zhou et al.  Supplement 
2 
Detailed Supplemental Methods and Materials 
 
Antibodies and chemical reagents 
Antibodies against CDK5 (#2506), CDK substrate (#9477), PSD95 (#3450); cleaved 
caspase-3 (#9661); β-actin (#4970), GAPDH (#5174) and phospho-Rb (Ser807/811) (#9308) 
were purchased from Cell Signaling Technology. Anti-CDK5 (sc-6247); GFP (sc-8334); 
p35/p35 (sc-820/821); V5(sc-83849) and GAPDH (sc-47724) antibodies were purchased from 
Santa Cruz Biotechnology. Anti-a-tubulin (T5168); Synaptophysin (SAB4502906) and 
anti-Flag (M2) (A2220) antibodies were purchased from Sigma Aldrich. Anti-BAG3 
(ab86298) and PSD95(ab12093), GLUR1(ab31232), GLUR2 (ab20673) and NR2B (ab65783) 
antibodies were purchased from Abcam. Anti-Syntaxin 1 (YT5440) antibody was purchased 
from Immunoway. Anti-Synapsin-I (AB1543), NR2A (#07-632), CDK5 (#05-364) antibodies 
were purchased from Millipore. Anti-GST (HRP-66001) antibody was purchased from 
ProteinTech. Anti-BAG1 (PA5-29585); BAG2 (PA5-30922); BAG3 (PA5-54239) and HSP70 
(MA3-006) antibodies were purchased from ThermoFisher. Anti-beta-amyloid (GTX82974) 
and amyloid-precursor protein (GTX101336) antibodies were purchased from GeneTex.  
 
The custom-made rabbit antibody against phosphorylated Ser297 of BAG3 was generated by 
ProSci Incorporated (Poway, CA). In brief, rabbits were inoculated with a BAG3 
phospho-peptide (PLHSP(pS)PIRVH) to induce an immune response. Subsequent serum 
fractionation using both negative- and positive-affinity purification methods was performed to 
optimize the specificity for the targeted phospho-epitope.  
 
Secondary antibodies used for immunocytochemistry assay were listed as follows: goat 
anti-mouse Alexa-488 and -594; as well as goat anti-rabbit Alexa-488 and -594 antibodies 
were purchased from ThermoFisher. Special reagents, such as human amyloid-beta peptide 
(1-42) (#1428) was purchased from Torcis. Magnetic Dynabeads for co-immunoprecipitation 
were purchased from ThermoFisher. Unless otherwise specified, all chemicals and reagents 
were purchased from Sigma.  
 
Animal maintenance, brain tissue isolation, and primary neuron culture 
Regarding to mouse colonies in Xiamen University: C57BL/6 mice were directly purchased 
from Xiamen University Laboratory Animal Center. The 5XFAD 
[B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax],  APP/PS1 
[B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax] AD-model, and Nestin-Cre 
[B6.Cg-Tg(Nes-cre)1Kln/J] were obtained from Model Animal Research Center of Nanjing 
University. BAG3-conditional knockout (cKO) mice (BAG3f/f) were generated with custom 
service from Beijing Biocytogen Co., Ltd. All animal experiments were approved by and 
conducted in accordance with the guidelines of the Animal Ethics Committee of Xiamen 
University. 
 
Mouse brain tissues were harvested as previously described (1). In brief, adult mice were 
anesthetized with intraperitoneal administration of 1.25% (vol/vol) Avertin at a dosage of 30 
mL/kg body weight. The heart of each mouse was then surgically exposed; the left chamber 
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was catheterized; the right atrium was opened. Chilled physiological saline was perfused 
trans-cardially for 3 minutes to elute blood from the body. After perfusion, the cranial bones 
were opened; cortex and hippocampus tissues were harvested, snap-frozen in liquid nitrogen, 
and stored at -80 oC until use. 
 
Primary neuronal culture was prepared as previously described (1). In brief, cortical neurons 
were disintegrated from cortical tissues of embryonic day 16.5 (E16.5) mouse pups (primary 
hippocampus neurons were disintegrated from hippocampal tissues of P0 mouse pups). 
Embryos were collected in ice-cold PBS-glucose, and the cortical or hippocampal lobes were 
excised. Meninges were removed and the tissues were placed in 1X trypsin solution for 10 
minutes, with manual shaking at 5 min. After digestion, an equal volume of DMEM with 10% 
(vol/vol) FBS was added to inactivate the trypsin. Samples were then centrifuged at 2,500 
rpm for 5 min. Supernatant was removed, followed by transferring the pellet to fresh 
Neurobasal medium supplemented with B-27, penicillin/streptomycin (1X) and L-glutamine 
(2mM; GlutaMAX, Invitrogen) prior to gentle re-suspension. Tissue was triturated 10 times 
through a 5-mL pipette and allowed to settle to the bottom of a 15-mL conical tube. Cells in 
solution above the pellet were removed. Surviving cells were identified by trypan blue 
exclusion and counted before plating on poly-L-lysine-coated (0.05 mg/mL) glass coverslips. 
Unless otherwise specified, cells were plated in 24-well plates at 50,000 cells per well and 
allowed to mature for over 7-10 days in vitro (DIV) before transfection or lentiviral 
transduction. For other experiments, cells were grown for a minimum of 14 days in vitro 
(DIV14) before drug-treatment experiments. Every 3-day half of the culture medium was 
replaced with an equal volume of fresh medium to sustain the culture. 
 
Human brain tissues 
Human autopsy tissues harvested from eight individuals diagnosed with AD and eight 
age-matched controls were obtained from the NICHD Brain and Tissue Bank of 
Developmental Disorders at the University of Maryland, Baltimore, MD [NICHD Brain 
Tissue Bank for Developmental Disorders and NICHD (Contract #N01-HD-4-3368 and 
N01-HD-4-3383)] (details on samples, are listed below). Frozen brain tissues were embedded 
in Tissue-Tek Cryo-O.C.T. compound and sectioned at 10 µm. All AD cases were confirmed 
both clinically and by post-mortem examination. The average age of the subjects was 75 years 
for the AD patients and 72.5 years for non-demented controls (NDCs). The non-AD controls 
were free of any known CNS neurological diseases at the time of death. 
 
Case Details 
Sample 
ID 
Disorder Sex Age (Years) Race Postmortem 
Interval (Hours) 
4512 AD M 77 Caucasian 3 
1946 AD M 68 Caucasian 5 
5007 AD F 76 Caucasian 15 
5504 AD F 73 Caucasian 22 
4697 AD M 78 Caucasian 23 
4693 AD F 70 Caucasian 12 
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5195 AD M 80 Caucasian 9 
5590 AD F 78 Caucasian 17 
4789 AD F 72 Caucasian 19 
5572 NDC F 70 African American 24 
5604 NDC F 73 Caucasian 20 
5661 NDC M 70 African American 12 
4921 NDC F 73 Caucasian 13 
5755 NDC M 72 Caucasian 15 
5830 NDC M 75 Caucasian 18 
5840 NDC M 75 Caucasian 17 
 
Sample preparation, LC-MS/MS and proteomics analyses 
LC-MS/MS and proteomic analyses were performed as previously described with slight 
modifications (2, 3). Mouse primary cortical neurons pre-expressed with either GFP-only, 
GFP-tagged BAG3 or GFP-tagged HSP70 for 72 hours were harvested. Lysates were 
immunoprecipitated with anti-GFP antibody conjugated to magnetic Dynabeads® (Life 
Technologies). The enriched proteins were resolved by 7.5% SDS-PAGE gel. Lanes 
containing GFP-only or GFP-fused protein interacting proteins were cut into smaller 
fragments and washed with 25 mM NH4HCO3/ 50% Acetonitrile (ACN) until it became 
colorless. Gel fragments were shrunk in ACN for 15 minutes, centrifuged to remove 
supernatant. Proteins in the residual gel fragments were reduced in 10 mM DTT at 55oC for 
45 minutes, followed by alkylation in 55 mM Iodoacetamide (IAA). Each segment was then 
digested with mass spectrometry grade Trypsin (Promega) in 1:50 (w/w) overnight at 37oC. 
Digested peptides were extracted using 25 mM NH4HCO3 and 5 % formic acid/ 60% ACN, 
speed dried and re-dissolved in 0.5% formic acid, which was then desalted in a μC18 
reverse-phase ZipTip (Millipore). Eluted samples were analyzed on a LTQ Velos mass 
spectrometer (Thermo Scientific), which coupled to a Thermo Accela LC with a 
nano-electrospray ionization source. One microgram of digested protein was enriched on a 
trap column (Zorbax X300 SB-C18, 5 x 0.3 mm, 5 μm particle size) and separated on a C18 
column (Thermo Bio-Basic-18, 150 x 0.1 mm, 300 Å pore size, 5μm particle size) at a flow 
rate of 220 μL/min. The composition of LC solvent A was 0.1 % formic acid in water and 
solvent B was 0.1 % formic acid in acetonitrile. The LC mobile phase was maintained at 2% 
of solvent B for 2 minutes after sample loading. The gradient of the LC started by increasing 
solvent B from 2 % to 8 % for 8 minutes and then to 45 % for 33 minutes. After that, the 
gradient was quickly increased to 80 % within 2 minutes and then kept stabilized for 9 
minutes; followed by a drop to 2 % within 1 minute and maintained as such for 9 minutes for 
equilibration before the next injection. For mass spectrometry analysis, each MS1 was 
followed by 5 MS2 of the 5 most intense ions observed in MS1 scan. The dynamic exclusion 
time was 60 seconds. Collision included dissociation (CID) was used in MS2 and the 
normalized collision energy was set at 35%. Peptides and proteins were identified using the 
Mascot Server (Version 2.3, Matrix Science). Databased used was Swissprot/NCBI and the 
taxonomy was set as mouse. The search criteria were set as follows: (1) trypsin digestion with 
two allowed missed cleavage; carbamidomethylation on cysteine as a fixed modification, and 
oxidation on methionine as variable modification.  
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SILAC phospho-proteomic analysis 
Global phosphoproteomic analysis was performed as described previously with slight 
modifications (4, 5). SILAC N2a cells were grown for 6 doublings in either one of the SILAC 
media. Control cultures were grown in medium containing unlabeled amino acids (R0K0). 
Experimental cultures were grown in heavy weighted amino acids (arginine with six 13C plus 
four 15N substitutions and lysine with four 2H and two 15N substitutions – R10K8). In all 
cultures, 98% labeling efficiency was achieved. Cells grown in the R10K8 medium were 
transfected to overexpress with p35 alone or both CDK5 and p35. Cultures were maintained 
for an additional 48 hours before harvesting. 1.5 mg of cell lysates from both cultures were 
mixed in a 1:1 ratio and separated by NuPAGE 10% Bis-Tris Gel electrophoresis (Thermo 
Fisher). Gels were sliced into 10 pieces, followed by reduction with DTT, alkylation with 
iodoacetamide and digestion with trypsin (Promega) overnight at 37°C. Peptides were 
extracted twice with 5% formic acid, 60% acetonitrile (CAN) and dried under vacuum. 
Extracted peptides were then subjected to phosphoproteins enrichment, using Titansphere 
Phos-TiO kit (Fisher Scientific) following manufacturer’s instructions. Enriched 
phosphopeptides were then analyzed by NanoLC-MS/MS (Ultimate 3000 RLSCnano System 
linked to Velos LTQ Orbitrap, Thermo Fisher). In brief, peptides were solubilized in 0.1% 
Trifluoroacetic acid (TFA) and loaded on to a self-made fused silica trap-column of 
100umX2cm packed with Magic C18 AQ (5um bead size, 200Å pore size, Michrom 
Bioresources, Inc.) and washed with 0.2% formic acid at a flow-rate of 10ul/min for 5 min. 
Retained peptides were separated on a fused silica column of 75um x 50cm self-packed with 
Magic C18 AQ (3um bead size, 200Å pore size, Michrom Bioresources, Inc.) using a linear 
gradient from 4 to 50% B (A: 0.1% formic acid, B: 0.08% formic acid, 80% ACN) in 155 min 
at a flow-rate of 300 nl/min. A top 10 method was used for mass spectrometry. For each cycle, 
one full MS was scanned in the Orbitrap with a resolution of 60000 from 300-2000 m/z 
followed by HCD fragmentation of 10 most intense peaks with collision energy of 40% and 
scanned in Orbitrap with 7500 resolutions. Data-dependent acquisition was set for repeated 
count of 2 and exclusion of 60 sec. MS/MS spectra were searched via MASCOT 2.3 against 
IPI mouse database v. 3.26 using the following parameters: precursor mass tolerance 10 ppm, 
fragment mass tolerance: 0.01 Dalton, static modification of carbamidomethylation on 
cysteine (+57.0214) and dynamic modification for phosphorylation on serine, threonine and 
tyrosine (+79.96630), methionine oxidation (+15.9949), 13C6-arginine (+6.02), 
13C615N4-arginine (+10.008), 2H4-lysine (+4.025) and 13C615N2-lysine (+8.014). The peptide 
identification results were filtered using FDR of 1% and only the top match was used for each 
identified spectrum. Precursor quantitation was performed using Proteome discoverer 1.2 
with mass precision 3ppm.  
 
Intracranial injections into neonatal mice 
Procedures were performed as previously described with slight modification (6). Within 6 
hours of birth, neonates were collected from cages, and anesthetized in aluminum foil 
immersed in ice for 3-5 min before injection. Cryo-anesthesia was confirmed when pup 
movements were ceased, and their skin color changed from pink to light purple. Injection of 
AAV virus-carrying (1) scrambled shRNA and BAG3-targeting shRNA shuttles; or (2) 
GFP-vector or GFP-tagged BAG3 shuttles, in viral titers around 7.35 × 1012 was done to two 
Zhou et al.  Supplement 
6 
lateral ventricles. After injection, pups were monitored and allowed to completely recover on 
a warming blanket prior to returning to their home cage. At 30-day post-injection, mice were 
sacrificed, and brains were harvested for Golgi staining and electrophysiology experiments. 
Alternatively, some mice were kept until 60-days post-injection and subjected to behavioral 
tests (which almost lasted for an additional month) prior to being sacrificed for additional 
biochemical analyses around Day90 post-injection. 
 
Western blotting and co-immunoprecipitation 
Immunoblotting and co-immunoprecipitation were performed as described previously (1). 
Briefly, harvested cells were homogenized in ice-cold NP-40 lysis buffer with protease 
inhibitor mix (Roche). The samples were centrifuged at 12000g for 15 min at 4°C. The 
supernatant was collected, and total protein levels were quantified by micro BCA protein 
assay kit (Thermo Fisher). For Western blots, the lysates were separated with SDS-PAGE 
followed by transferring onto nitrocellulose membranes. Membranes were blocked with 5% 
non-fat milk in TBST and then probed with primary antibodies at different concentrations 
according to manufacturer’s instructions overnight at 4oC. On the next day, membranes were 
washed thrice with TBST, followed by incubation with horseradish peroxidase-linked 
secondary antibodies for 1 hour at room temperature. After another round of washing with 
TBST, chemiluminescent Western ECL detection reagents (Pierce) was used to illuminate the 
signals. Intensities of immune-reactive bands were quantified using the Image J software 
(NIH). For immunoprecipitation, cell lysates were incubated with immunoprecipitation 
antibody at 4°C for 4 hours, followed by overnight incubation with protein G beads. The 
beads were then washed five times with ice-cold NP-40 lysis buffer, and the bound proteins 
were analyzed by SDS-PAGE and immunoblot analysis as mentioned above. 
 
Immunohistochemistry and immunocytochemistry 
Procedures were performed as previously described with slight modifications (1, 7). For 
immunostaining, primary neurons were grown on 13-mm coverslips (Marienfeld) in 24-well 
plates. At appropriate times cultures were fixed with fresh 4% (wt/vol) paraformaldehyde 
(Sigma-Aldrich) for 10 min, followed by permeabilization with 0.3% Triton X-100 in PBS for 
10 min. After blocking with 5% (wt/vol) BSA in PBS for 1 hour, primary antibodies were 
added and allowed incubation overnight at 4 °C. The following day, coverslips were washed 
three times (10 minutes each) with PBS. After rinsing, secondary antibodies were added and 
incubated for 1 hour at room temperature. Three additional washes with PBS were done to 
remove excess secondary antibodies. The coverslips were then inverted and mounted on glass 
slides using the ProLong Gold Antifade Reagent (Thermo Fisher). Immunofluorescence was 
analyzed and Z-stacked maximum projected images were photographed using a TCS Sp8 
confocal microscope (Leica Microsystems Inc.). 
 
For immunostaining of brain sections, antigen retrieval was performed by treating the 
mounted cryostat sections with citrate buffer at 95 °C for 15 minutes followed by cooling to 
room temperature for 1 hour. Sections were rinsed in PBS, blocked with 5% (vol/vol) donkey 
serum/PBS for 1 hour before immune-staining procedure as above. 
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GST-pull down 
Glutathione-S-transferase (GST) fusion protein expression pull-down served as an affinity 
capture of one or more proteins (either defined or unknown) in solution by its interaction with 
the GST fusion probe protein and subsequent collection of the interacting proteins through the 
binding of GST to glutathione-coupled beads. The protocol was performed according to the 
manufacturer’s instructions (ThermoFisher). 
 
In vitro and intracellular CDK5 kinase assay 
For in vitro CDK5 kinase assays were carried out as described in the New England Biolabs 
protocol. Briefly, recombinant active CDK5/P35 complex was incubated in the following 
reaction conditions: 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 M sodium 
vanadate, 1.2 mM DTT, ATP, 1 µg of full-length GST-BAG3, GST-BAG3-S297A, or 
GST-BAG3-T285A were added as the substrate. Kinase reactions were separated by 
SDS-PAGE gel electrophoresis and analyzed by autoradiography or by immunoblotting using 
the CDK substrates antibody. For CDK5 activity measurement inside cells treated under 
different conditions, active CDK5 immunoprecipitation and kinase assay were performed as 
previously described (8).   
 
Preparation of synaptosomal and PSD fractions 
Synaptosomal and PSD fractions were prepared as previously described (9). Briefly, primary 
cortical neurons (DIV14) were collected in cold HEPES-buffered sucrose (HBS=0.32M 
sucrose and 25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH=7.4). 
The homogenates were centrifuged at 500g for 5 min to separate the supernatant (S1) from 
the nuclei and large debris fraction. The S1 fraction was centrifuged at 10,000g for 12min to 
separate the supernatant (S2, light membrane and cytosolic fraction) and the pellet (P2, crude 
synaptosomal fraction). The P2 fraction was re-suspended in cold HBS buffer (25 mM 
HEPES, pH=7.4, and 150mM NaCl) to obtain the synaptosomal fraction. The PSD fraction 
was prepared by solubilizing the synaptosomal fraction in 1% Triton HBS buffer and 
centrifuging at 10,000g for 20 min. Solubilized pellets were re-dissolved in 3% 
SDS-containing HBS buffer and used for subsequent analyses. 
 
Cell culture and transfection 
Cell culture and transfection were performed as previously described (1, 7). Mouse 
neuroblastoma N2A, hippocampal cell line HT22 and Human HEK293T cells were cultured 
in high glucose DMEM medium containing 10% FBS, 100 unit/ml penicillin, and 100unit/ml 
streptomycin. Cells were maintained at 37°C and 5% CO2. Primary cortical neurons were 
cultured as mentioned above. For transfection into cell lines, DNA constructs were transfected 
with Lipofectamine 2000 (Thermo Fisher) following the manufacturer’s protocol. For 
transfection into primary neuronal cultures, DNA constructs were transfected with 
Lipofectamine LTX (Thermo Fisher) in the presence of Plus Reagent following the 
manufacturer’s protocol. At 5 hours after transfection, cells were refreshed with a new culture 
medium (or conditioned medium for primary neurons) and further incubated for 48-72 hours 
to allow recovery and ectopic expression of transfected constructs. 
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Quantitative RT-PCR (qPCR) analysis 
Quantitative RT-PCR analysis was performed as previously described with slight 
modifications (1). Total cellular RNA was isolated from brain cortex tissues or cultured cells 
using the RNeasy mini kit (Qiagen) following the manufacturer’s protocol. RNA was then 
reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturer’s instructions. The resulting cDNA was analyzed 
by qRT-PCR using SYBR Green PCR Master Mix (Applied Biosystems). All reactions were 
performed in a Roche LightCycler (LC) 480 instrument using the following protocol: 
pre-incubation at 95 oC for 15 min (1 cycle); denaturation at 94 oC for 15 seconds, annealing 
and extension at 55 oC for 30 seconds (40 cycles), melting at 95 oC for 5 seconds, 65 oC for 60 
seconds and 95 oC continues (1 cycle) followed by cooling at 40 oC for 30 seconds. The 
specificity of the primers was confirmed by observing a single melting point peak. qPCR 
efficiency was calculated from the slope was between 95 and 105% with co-efficiency of 
reaction R2=0.98-0.99. A total of 7-9 biological replicates x 4 technical replicates were 
performed for each treatment group. Data were analyzed using the comparative Ct method 
(ΔΔCt method). 
 
Golgi staining and Dendritic and spine analyses 
Golgi staining was performed using the FD Rapid Golgi Stain kit (FD Neuro Technologies). 
The experiments were performed in accordance with the protocol of the Kit. In brief, freshly 
dissected brains were immersed in solution A and B in FD Rapid Golgi Stain kit for 2 weeks 
at room temperature (A switch from solution A to B occurred on Day 1). After that, samples 
were transferred to solution C for incubation at 4ºC for 24 hours. After 24 hours, samples 
were refreshed in new solution C to allow an extra round of incubation for 3-5 days at 4 ºC. 
Brains were sliced with at a thickness of 150 µm. The Golgi-stained neurons and dendritic 
segments in hippocampal CA1 and layer II/III of the cortex were imaged with the Axio 
Imager microscope (Carl Zeiss). The Extended Focus module was used to compress Z-stack 
images into one single image. The pyramidal neurons in cortical layers II/III and in the CA1 
region of the hippocampus were also analyzed. Neurons were randomly selected per region in 
each mouse. Two segments were randomly chosen per neuron from both the apical oblique 
and basal shaft (BS) dendrites, and the numbers of spines were counted and quantified in 
blind. 
 
Plasmids, small interference RNA (siRNA) and BAG3-AAV 
Site-directed mutagenesis (Stratagene) was used to generate pointed-mutated BAG3 
constructs, including GFP-BAG3-S297A, GFP-BAG3-S297D and GFP-BAG3-T285A. For 
the generation of GST-tagged BAG3 constructs, including GST-BAG3-WT, 
GST-BAG3-S297A and GST-BAG-297D, wild type or point-mutated BAG3 fragments were 
generated by the PCR method, followed by sub-cloning into the Mrfp-GST-4T-1 and a 
lentiviral pLX304 V5-fusion backbone expression vector. For the GFP backbone, 
FLAG/GFP-p25, FLAG/GFP-p35, FLAG/GFP-CDK5 vectors were obtained or generated as 
previously described (10, 11). The EGFP-HSP70 (HSPA1A) (#15215) was obtained from 
Addgene (12). Gene-specific siRNAs targeting Hspa1a, Cdk5 and Bag3 were purchased from 
Thermo Fisher. The AAV-based shRNA against BAG3, including 
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AAV-CAG-EGFP-U6-scramble-shRNA and AAV-CAG-EGFP-U6-shBAG3-1-3 were 
purchased from OBiO biotech Shanghai. The AAV-based construct for overexpression of 
BAG3, including the AAV-CMV-GFP-WPRE-pA (backbone) and 
AAV-CMV-BAG3-GFP-WPRE-pA were purchased from BrainVTA biotech (Wuhan, China). 
 
Production and purification of AAV virus 
AAV virus were produced and purified as previously described with slight modifications (13). 
The pAAVs and two helper plasmids were used for AAV production: 1. pHelper (Stratagene) 
expresses the adenovirus helper functions (E2A, E4 and VA genes), and the other helper 
plasmid, 2. pBSIISK-R2C1, expressing the replication protein of AAV serotype 2 (Rep2) and 
the capsid protein of AAV serotype 1 (Cap1), was newly prepared by inserting the following 
fusion sequences into the XhoI/NotI sites of pBSIISK: 1) nucleotides 146–2,202 of wild-type 
AAV2 genome (GenBank accession number, AF043303.1); 2) nucleotides 2,223–4,433 of 
AAV1 (AF063497.1); and 3) nucleotides 4,438–4,534 of AAV2. Production and purification 
of AAV were performed as reported previously. Briefly, pAAVs, pHelper, and pBSIISK-R2C1 
were co-transfected into HEK293T cells (RCB2202, Riken, Japan) by using 
polyethyleneimine (23966; Polysciences, Inc., Warrington, PA). The medium was replaced 6 
h after transfection with Dulbecco’s modified Eagle’s medium (11965–092; Life Technologies) 
containing 10% fetal bovine serum, 4 mM l-glutamine (25030–081; Life Technologies), 2 
mM GlutaMAX™ (35050–061; Life Technologies), 0.1 M non-essential amino acids 
(35050–061; Life Technologies), and 1 mM sodium pyruvate (11360–070; Life Technologies). 
Cells containing virus particles were collected 72 h after medium replacement. After 
extraction by three cycles of freeze-and-thaw, the virus particles were purified from a crude 
lysate of the cells by ultracentrifugation with OptiPrep (AXS-1114542; Axis-Shield, Oslo, 
Norway) and then concentrated by ultrafiltration with Amicon Ultra-15 Centrifugal Filter Unit 
with Ultracel-50 membrane (UFC905024; Merck Millipore, Darmstadt, Germany). 
 
Lentivirus production and transduction  
Lentivirus stocks were produced as previously described with slight modifications (14). 
Human embryonic kidney 293FT cells (Invitrogen) were transfected using Lipofectamine 
2000 (Thermo Fisher) with the expression of two helper plasmids: psPAX2 and pMD2.G. Ten 
micrograms of the transfer vector, 5g pMD2.G and 5 g psPAX2 of DNA were used per 
10-cm plate. Forty-eight hours after transfection, the supernatants of four plates were pooled, 
centrifuged at 780 x g for 5 minutes, filtered through a 0.45-m pore size filter, and further 
centrifuged at 24,000 rpm for 2 hours. The resulting pellet was re-suspended in 100L of PBS. 
Lentivirus titration was performed with a p24 ELISA (Cell BioLabs). Lentivirus transduction 
to primary cortical neurons was performed on DIV5-6 at titer range 10^7 IU/ml. In most 
experiments, cultures were infected overnight, rinsed twice with virus-free medium the next 
morning and incubated in normal culturing medium for another 48-72 hour prior assay. 
 
Multiple protein sequence alignment 
Protein sequences of BAG3 in Homo sapiens (human) [NP_0004272.2], Pan troglodytes 
(chimpanzee) [XP_508072.3], Mus musculus (mouse) [NP_038891.4] Macaca mulatta 
(Rhesus monkey) [NP_001252986.1] and Rattus norvegicus (rat) [NP_001011936.1] were 
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obtained from the NCBI-Gene database https://www.ncbi.nlm.nih.gov/gene . Multiple protein 
sequence alignment was performed on the Clustal Omega platform 
https://www.ebi.ac.uk/Tools/msa/clustalo/ (15). Conserved S/TP sites among all the species 
analyzed were manually identified for subsequent analysis.  
 
Electrophysiological recording 
Brain slices were prepared as previously reported with slight modifications (Wen et al., 2011). 
In brief, transverse hippocampal slices (0.40 mm) were prepared using a Vibroslice (VT 
1000S; Leica) in an ice-cold solution containing 64 mM NaCl, 2.5 mM KCl, 1.25 mM 
NaH2PO4, 10 mM MgSO4, 0.5 mM CaCl2, 26 mM NaHCO3, 10 mM glucose, and 120 mM 
sucrose. Slices were allowed to recover for 30 min at 32°C and then at room temperature (25 
± 1°C) for at least 1-hour prior initiation of recording in the artificial cerebrospinal fluid 
(aCSF) containing 126 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM MgSO4, 2 mM 
CaCl2, 26 mM NaHCO3, and 10 mM glucose. Slices were transferred to the recording 
chamber and perfused with aCSF (2 ml/min) at 32°C. All solutions were saturated with 95% 
O2/5% CO2 (volume/volume). fEPSPs were evoked in the CA1 stratum radiatum by 
stimulating the SCs pathway with a two-concentrical bipolar stimulating electrode (25-mm 
pole separation; FHC, Inc) and were recorded using a MultiClamp 700B amplifier (Molecular 
Devices) with aCSF-filled glass pipettes. Test stimuli consisted of monophasic 100-μs pulses 
of constant currents (with intensity adjusted to produce 25% of the maximum response) at a 
frequency of 0.0167 Hz were used. The strength of synaptic transmission was determined by 
measuring the initial (10–60% rising phase) slope of fEPSPs. LTP in the CA1 area was 
induced by one train of 100-Hz stimuli with the same intensity of the test stimulus, and a cut 
was made between CA1 and CA3 in hippocampal slices to prevent the propagation of 
epileptiform activity.  
 
Whole-cell patch-clamp recordings were performed on CA1 pyramidal neurons which were 
visualized using an infrared differential interference contrast microscope with a 40× water 
immersion lens and an infrared-sensitive charge-coupled device camera. All experiments were 
conducted in neurons located within the cell-dense band CA1 region. Whole-cell patch-clamp 
recordings were performed using an amplifier (Axon Multiclamp 700B) and digitized by 
pClamp software (version10.5; Molecular Devices). Both mEPSCs and mIPSCs were 
recorded at a holding potential of -65 mV. For mEPSC recording, glass pipettes were filled 
with the solution containing 120 mM K-gluconate, 20 mM KCl, 10 mM Hepes, 0.1 mM 
EGTA, 2 mM MgCl2, 10 mM sodium phosphocreatine, 0.2 mM leupeptin, 4 mM Mg-ATP, 
and 0.3 mM Na-GTP, pH 7.3 (280 mOsm). For mIPSC recording, the same pipette solution 
was used except that the K-gluconate was substituted with 140 mM KCl (final concentration). 
NMDA receptor-mediated mEPSCs were recorded in a modified aCSF (0 mM MgSO4, 5 mM 
KCl, and 1.6 mM CaCl2). For evoked EPSC (eEPSC) and eIPSC recording, K-gluconate was 
substituted with 120 mM CsCH3SO3, and 5 mM lidocaine N-ethylchloride (QX-314) was 
added in the pipette. AMPA and NMDA receptor-mediated EPSCs were recorded at a holding 
potential of -65 mV and +40 mV, respectively; eIPSCs were recorded at a holding potential of 
-65 mV. 1 μM tetrodotoxin was included in the perfusion solution for mEPSC and mIPSC 
recording. For mEPSC and eEPSC recordings, 20 μM bicuculline was used to block GABAA 
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receptor-mediated currents, and NMDA receptor-mediated eEPSCs were recorded in the 
presence of 20 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). For mIPSC and eIPSC 
recording, 50 μM DL-2-amino-5-phosphonovaleric acid and 20 μM CNQX were 
supplemented to block NMDA and AMPA receptors, respectively. Stock solutions of all drugs 
were diluted to working concentrations in the extracellular solution immediately before use 
and applied by continuous superfusion. eEPSCs and eIPSCs were generated with a 
two-concentric bipolar stimulating electrode (FHC, Inc) positioned 200-300 μm from the 
neuron under-recording. Data were filtered at 2 kHz and sampled at 10 kHz. Neurons with a 
resting potential of at least -60 mV and resistance fluctuated within 15% of initial values (<20 
MΩ) were analyzed. Mini events were analyzed with MiniAnalysis software (Synaptosoft, 
Inc.).  
 
Animal behavioral tests 
All tests were performed as previously described with slight modifications (16). At 60 days 
after injection with AAV virus, mice were subjected to various behavioral tests. All mice were 
housed in groups of five per cage. All behavioral tests were performed during the light phase 
of the circadian cycle between 09:00 and 17:00. All behavioral testing began on Day 8 of the 
course and mice were allowed 2 hours to habituate to the testing rooms before tests. 
Experiments were performed blind to the genotype when behavioral tests were carried out. 
With an overhead camera and the Freeze Frame software (Actimetrics), learning and memory 
performance were assessed using the Morris water maze, T/Y maze; novel object recognition 
tests; fear conditioning and freezing behavior were measured as well. Followed by these, 
experimental mice were also subjected to open field test, elevated plus maze test, forced swim 
test and rotarod test.  
 
Morris water maze test. The Morris water maze test was conducted as described previously 
(17). Briefly, a blue circular tank (90 cm (diameter)*35 cm (high)) was filled with water 
(~22°C), and a platform (10 cm in diameter) was submerged 1 cm beneath the surface of the 
water in a target quadrant. The walls surrounding the tank contained bright and contrasting 
shapes that served as reference cues. Training was conducted over 7 consecutive days with 
four trials/day using an inter-trial interval of 1–1.5 min. Mice were placed randomly into each 
of four starting locations for each of four daily training trials. In each trial, mice swam until 
they found the hidden platform or were gently guided to it by the experimenter if not found 
within 60 seconds. Mice remained on the platform for 15 seconds before returning to the 
home cage. Daily data were averaged across the four trials. On day 7, a probe trial was 
conducted and the hidden platform was removed, mice were placed in the pool and allowed to 
swim for 60 seconds. The time spent in each of the four quadrants, and the number of target 
(platform) area crossings, were recorded. 
 
T/Y maze. The T/Y-maze was used for the evaluation of spontaneous alternation for spatial 
working memory in mice. Each session began with the placement of the mouse at the center 
of the maze. The mouse was allowed to explore the three arms for 5 min freely. Arm entry 
was defined as all four limbs within the arm. A triad was defined as a set of three arm entries 
when each entry was to a different arm of the maze. Total travel distance, the number of arm 
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entries and the number of triads were recorded. Spontaneous alternations were defined as 
consecutive triplets of different arm choices. 
 
Novel object recognition test. The novel object recognition test is based on the innate 
tendency of rodents to explore novel objects over familiar ones differentially. The test was 
performed as previously described (18). On the first day, mice were placed into a Plexiglas 
rectangular cage (40cm (L) × 40cm (W) × 40cm (H)) for 10 min. On the second day, mice 
were presented with two of the same objects, indicated as A and B. Twenty-four hours later, 
the mice were exposed to two different objects: A and C, with C indicating a novel object. All 
objects were rinsed with ethanol and allowed to dry between trials and before the first trial. 
All testing and training sessions were videotaped and analyzed in blind to the treatment group 
of the animals. Object exploration was defined as each instance in which a mouse’s nose 
touched the object or was oriented toward and within 2 cm of the object. Exploratory activity 
within the experimental arena was measured over a five- minute trial with a computer timer. 
 
Open-field test. Mice were placed in the center of an open-field arena (40cm (L) × 40cm (W) 
× 40cm (H)) for 10 min. During the experiments, the entire open field was video recorded. 
Total travel distance and time spent in the center areas of the maze were computed by a Smart 
3.0 video tracking system (Panlab, Harvard Apparatus). 
 
Elevated plus maze test. Mice were placed at the center of a white Plexiglas elevated plus 
maze (30 cm (Long) × 6 cm (Wide) × 15cm (High)) and were allowed to explore for 5 
minutes (19). The Mice were monitored using CleverSys TopScan Software, and time spent in 
and number of entries into the open and closed arms were measured.  
 
Rotarod test. Mice were placed on a stationary rotarod (IITC Life Sciences) in a well-lit room 
that was then activated and accelerated from 0 to 45 revolutions/ min over 5 min. The latency 
of mice to fall off the rod or taking one revolution was measured. Trials were repeated four 
times with intertribal intervals of 30 minutes over a single day.  
 
Forced swim test. The forced swim test was used for evaluation of the depressive-like 
behaviors. The tanks (15cm (D) × 30cm (H)) were filled with tap water set at 22°C. Mice 
were placed in the water and their escape-related mobility behavior was measured for 8 min. 
 
Quantitation and statistical analysis 
All data were obtained from at least three different preparations. Each preparation contains a 
biological sample number not less than 3. Statistical analysis of the data was performed with 
an unpaired Student’s t-test or a one-way ANOVA using Graphpad Prism 5. Data are 
presented as the Mean ± SEM. P values <0.05 represents statistical significance. 
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Supplementary Figures 
 
 
Supplementary Figure S1. Bag3 knockdown reduced synapses in neurons. (A) 
Representative blots showing the efficiency of Bag3 knockdown in HT22 cells or primary 
neurons transfected with the shRNA shuttles, and that by AAV-transduction to primary 
neurons. Quantification is shown (N=6). (B) Representative blots showing changes in levels 
of SYN1, SYP and PSD95 in primary neurons upon Bag3 knockdown. Quantification is 
shown (N=6). (C) Representative immunocytochemical images of neurons showing changes 
in SYN1 and SYP signal abundance on neurites upon Bag3 knockdown. Quantification is 
shown (N=6). (D) Bodyweight assessment in mice on Day 30 after receiving AAV injection to 
the prefrontal cortex and hippocampal area (N=6). Unless otherwise specified, all experiments 
were performed with at least 3 biological repeats; each individual assay was performed three 
times at least. *P<0.05, **P<0.01, ***P<0.001, ns=non-significant. Data represent the mean 
± SEM. 
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Supplementary Figure S2. Golgi staining analysis in structure and morphology of 
prefrontal cortex and primary neurons. Golgi staining analysis of effects of Bag3 
knockdown on neuronal morphology in (A) the brain prefrontal cortex region and (B) 
cultured primary cortical neurons. Quantification of neurite branching numbers relative to the 
distance from center is shown (N=6). (C-D) Representative images showing the changes in 
the complexity of neurite structures and the number of dendritic spines in cortical neurons 
located in (C) layer 2 and (D) layer 5 of the prefrontal cortex region. Quantification of spines 
number is shown (N=6). Unless otherwise specified, all experiments were performed with at 
least 3 biological repeats; each individual assay was performed three times at least. *P<0.05, 
**P<0.01, ***P<0.001, ns=non-significant. Data represent the mean ± SEM. 
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Supplementary Figure S3. Bag3 conditional knockout mice showed reduced synaptic 
abundance, cognitive and memory deficits. (A) Schematic diagram showing the design 
which selective knockout of Bag3 in neural lineage was achieved by mating Bag3f/f mice with 
Nestin-Cre mice. Exon 4 of Bag3 was excised by Cre-recombinase. (B) Survival curves; (C) 
body and brain weights of Nestin-Cre controls and Nestin-Cre Bag3f/f mice (N=6). (E) 
Representative blots showing changes of GLUR1 and NR1 levels in response to Bag3 
conditional knockout in cortex and hippocampal tissues (N=6). (F) Representative 
immunohistochemistry images showing the cellular location and levels of BAG3 in both 
hippocampal and cortex regions of brain samples harvested from Nestin-Cre controls and 
Nestin-Cre Bag3f/f mice (N=8-16). Unless otherwise specified, all experiments were 
performed with at least 3 biological repeats; each individual assay was performed three times 
at least. *P<0.05, **P<0.01, ***P<0.001, ns=non-significant. Data represent the mean ± 
SEM. 
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Supplementary Figure S4. BAG3 is crucial for mediating excitatory but not inhibitory 
neurotransmissions. Electrophysiology recordings were performed on brain slices harvested 
from mice which had stereotaxically injected AAV carrying either scramble or Bag3 shRNA 
shuttle. All experiments were performed on Day30 post-injection. (A) Representative traces 
of AMPA receptor-mediated eEPSC and quantitative analysis of eEPSC amplitude in response 
to increases in stimulation intensity are shown. (B) Representative traces of NMDA 
receptor-mediated eEPSC and quantitative analysis of eEPSC amplitude in response to 
increases in stimulation intensity are shown. AMPA and NMDA receptor-mediated EPSCs 
were recorded at a holding potential of -65 mV and +40 mV, respectively. The stimulation 
intensities for each trace were 20, 40, 50 and 80 μA (saturating stimulus) (N=8-12). (C) 
Representative traces of mIPSCs in mice stereotaxically injected AAV carrying either 
scrambled or Bag3 shRNA. (D) Cumulative frequency plots of the inter-event interval (left) 
and quantitative analysis of the mean mIPSCs frequency (right). (E) Cumulative distribution 
plots (left) and mean mIPSC amplitude (right). (F) Representative traces of eIPSCs (20, 40, 
50, and 80 μA) and quantification analysis of the eIPSC amplitude in response to increases in 
stimulation intensity are shown. (G) Representative traces (left) and quantification analysis of 
eIPSC paired-pulse ratio (right). The inter-spike intervals were 25, 50, 100 and 200 ms and 
signals were recorded from the whole-cell recordings of the hippocampal CA1 pyramidal 
neurons. Data were analyzed by unpaired t-test (for mean mIPSC amplitude and frequency), 
Kolmogorov–Smirnov test (for mIPSC cumulative histograms), and repeated measures (for 
eIPSC amplitude and paired-pulse ratio). Unless otherwise specified, all experiments were 
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performed with at least 3 biological repeats; each individual assay was performed three times 
at least. *P<0.05, **P<0.01, ***P<0.001, ns=non-significant. Data represent the mean ± 
SEM, N=8-13. 
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Supplementary Figure S5. BAG3 is crucial for memory and cognitive function.  (A) 
LTP was measured in Nestin-Cre control or Nestin-Cre Bag3f/f mice brain slice culture by 
stimulating SCs with a train of 100-Hz stimuli (N=10-18). (B-E) Morris water maze test was 
performed. (B) Initial latency time to target was recorded during the 4-day training course. 
(C-E) In the probe trial test performed on Day 5, (C) initial latency to target; (D) number of 
target-crossing and (E) time spent in the target zone and other quadrants (NE, SE and SW) 
were recorded (N=13-18). The number of triplet alternation was recorded in both (F) T-maze 
and (G) Y-maze paradigms (N=13-18). (H) Elevated-plus maze test which assesses 
anxiety-like behavior was performed. Quantification of time spent in the open arm is shown 
(N=13-18). (I) Forced-swimming test which accesses depressive behavior was performed. 
Quantification of immobility time is shown (N=13-18). (J) Rotarod test which accesses 
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locomotor capabilities was performed. Quantification of latency time to fall is shown 
(N=13-18). (K) Open-field test which also accesses anxiety-like behavior and motor function 
was performed. Quantification of time spent in the field center is shown (N=13-18). Unless 
otherwise specified, all experiments were performed with at least 3 biological repeats; each 
individual assay was performed three times at least. *P<0.05, **P<0.01, ***P<0.001, 
ns=non-significant. Data represent the mean ± SEM. 
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Supplementary Figure S6. BAG3 ectopic re-expression in AD-mouse rescued synaptic 
protein abundance. (A) Representative immunohistochemistry images showing changes in 
BAG3 signals in the hippocampal CA1 region of 5XFAD mice as compared to littermate 
controls (N=6). (B) Representative blots showing changes in levels of BAG3, HSP70 and 
selected synaptic proteins and their interactions in hippocampal samples harvested from 
5xFAD mice stereotaxically injected AAV carrying expression vector of BAG3 or empty 
vector control. Quantification of relative band intensities is shown in (D) (N=6). Unless 
otherwise specified, all experiments were performed with at least 3 biological repeats; each 
individual assay was performed three times at least. *P<0.05, **P<0.01, ***P<0.001, 
ns=non-significant. Data represent the mean ± SEM. 
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Supplementary Figure S7. Schematic diagram illustrating how CDK5 regulates BAG3 
stability and hence the abundance of synaptic proteins. (A) Under normal circumstances, 
dynamic activation of CDK5 by p35 phosphorylates and promotes the degradation of BAG3. 
Reduced level of BAG3— a co-chaperone of HSP70—alleviates its inhibitory effect against 
HSP70-mediated degradation synaptic proteins, in particular, those take part in glutamatergic 
neurotransmission. It is therefore the extent and duration CDK5 activation corresponds to 
intracellular stimuli thus act as a master regulator synaptic abundance and function, hence 
strength of neurotransmission and fidelity of cognitive and memory functions. (B) In 
neuropathological conditions such as AD, Aβ triggers robust calpain-mediated cleavage of 
p35 to p25. P25 is more stable than p35 therefore this persistently activates CDK5. CDK5, 
under these scenarios, chronically phosphorylates and promotes BAG3 degradation. Sustained 
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reduction of BAG3, in contrast to its dynamic fluctuation under normal conditions, aberrantly 
unleashes HSP70 and favors its role in facilitating protein degradation. As HSP70 selectively 
targets glutamatergic synaptic components in neurons, loss of these proteins thus impairs 
glutamatergic firing which is crucial for facilitating memory formation and cognitive 
function. 
Supplementary Table S1. List of phospho-peptides identified from SILAC (CDK5-P35 
screen).  
Supplementary Table S2. List of phospho-peptides identified from SILAC (P35 screen). 
Supplementary Table S3. Lists of unique BAG3-interacting candidates identified from 
mass spectrometry and the corresponding list of enriched functions indicated by Gene 
Ontology and KEGG analyses. 
Supplementary Table S4. Lists of unique HSP70-interacting candidates identified from 
mass spectrometry and the corresponding list of enriched functions indicated by Gene 
Ontology and KEGG analyses. 
Supplementary Table S5. Lists of common BAG3 and HSP70 interacting candidates 
identified from mass spectrometry and the corresponding list of enriched functions 
indicated by Gene Ontology and KEGG analyses. 
See Supplement 2 (Excel files) for all supplemental tables 
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